Konstantinos Tryfonidis

5.9k total citations · 2 hit papers
53 papers, 1.7k citations indexed

About

Konstantinos Tryfonidis is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Konstantinos Tryfonidis has authored 53 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 31 papers in Cancer Research and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Konstantinos Tryfonidis's work include Breast Cancer Treatment Studies (28 papers), Advanced Breast Cancer Therapies (18 papers) and HER2/EGFR in Cancer Research (18 papers). Konstantinos Tryfonidis is often cited by papers focused on Breast Cancer Treatment Studies (28 papers), Advanced Breast Cancer Therapies (18 papers) and HER2/EGFR in Cancer Research (18 papers). Konstantinos Tryfonidis collaborates with scholars based in Belgium, United States and Portugal. Konstantinos Tryfonidis's co-authors include Fátima Cardoso, Dimitrios Zardavas, Elżbieta Senkus, Martine Piccart, Leen Slaets, Javier Cortés, Maria João Cardoso, Rebecca Dent, Benita S. Katzenellenbogen and Y.H. Park and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Konstantinos Tryfonidis

53 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

2020 279 citations Peter Schmid, Roberto Salgado et al. Annals of Oncology profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Konstantinos Tryfonidis

Since Specialization

Citations

This map shows the geographic impact of Konstantinos Tryfonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantinos Tryfonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantinos Tryfonidis more than expected).

Fields of papers citing papers by Konstantinos Tryfonidis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Konstantinos Tryfonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantinos Tryfonidis. The network helps show where Konstantinos Tryfonidis may publish in the future.

Co-authorship network of co-authors of Konstantinos Tryfonidis

This figure shows the co-authorship network connecting the top 25 collaborators of Konstantinos Tryfonidis. A scholar is included among the top collaborators of Konstantinos Tryfonidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantinos Tryfonidis. Konstantinos Tryfonidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown → 2024 ·Annals of Oncology ·Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy, Javier Cortés, Rebecca Dent, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Y.H. Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fátima Cardoso, Ying Zhu, Wilbur Pan, Konstantinos Tryfonidis, Peter Schmid	47
2	Immunotherapy for hormone receptor‒positive HER2-negative breast cancer 2024 ·npj Breast Cancer ·Fátima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia	2
3	LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study 2024 ·Annals of Oncology ·(unknown), (unknown), R. Dent, (unknown), (unknown), Sherko Kümmel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jing Zhao, Xiaoyan Zhou, Konstantinos Tryfonidis, Gursel Aktan, (unknown)	5
4	A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers 2024 ·Oncology and Therapy ·Matthew Monberg, (unknown), Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker, Jaime Mejia, Robert Orlowski, Amin Haiderali, Vimalanand S. Prabhu, Gursel Aktan	1
5	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study 2023 ·Annals of Oncology ·Peter Schmid, Javier Cortés, Rebecca Dent, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Carsten Denkert, Y.H. Park, Rina Hui, (unknown), (unknown), Theodoros Foukakis, (unknown), (unknown), S-A. Im, Fátima Cardoso, Yu Ding, (unknown), Konstantinos Tryfonidis, Joyce O’Shaughnessy	20
6	LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer 2023 ·Annals of Oncology ·Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, (unknown), (unknown), Hiroyuki Yasojima, Yu Ding, (unknown), Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia	67
7	Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress) 2023 ·Cancer Research ·Erika Hamilton, Junji Tsurutani, Giuseppe Curigliano, Miguel Martín, Ciara C. O’Sullivan, Joohyuk Sohn, Konstantinos Tryfonidis, (unknown), (unknown), Véronique Dièras	1
8	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial 2022 ·Journal of Geriatric Oncology ·Lissandra Dal Lago, (unknown), Corneel Coens, Peter Vuylsteke, Giuseppe Curigliano, Barbara Brouwers, Agnieszka Jagiełło-Gruszfeld, Sevilay Altıntaş, Konstantinos Tryfonidis, Coralie Poncet, Andrew Bottomley, Berta Sousa, Étienne Brain, Hans Wildiers	8
9	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study breakdown → 2020 ·Annals of Oncology ·Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi	279
10	Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study 2019 ·SSRN Electronic Journal ·Peter Schmid, Roberto Salgado, Yeon Hee Park, Eva Muñoz‐Couselo, Sung‐Bae Kim, Joohyuk Sohn, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lina Yin, Anran Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi	4
11	Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial 2018 ·Breast Cancer Research and Treatment ·(unknown), K.C. Aalders, Nathan Touati, Konstantinos Tryfonidis, (unknown), Saskia Litière, Jonas Bergh, (unknown), David Cameron, Hervé Bonnefoi	1
12	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group 2018 ·The Lancet Oncology ·Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altıntaş, Nathan Touati, Fátima Cardoso, Étienne Brain	81
13	An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint ® ) 2017 ·European Journal of Cancer ·Maureen Makama, Caroline A. Drukker, Emiel J. Rutgers, Leen Slaets, Fátima Cardoso, M.A. Rookus, Konstantinos Tryfonidis, Laura J. van’t Veer, Marjanka K. Schmidt	10
14	Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial 2017 ·European Journal of Cancer ·K.C. Aalders, (unknown), Marieke E. Straver, Leen Slaets, Saskia Litière, Giuseppe Viale, Laura J. van’t Veer, Annuska M. Glas, Mauro Delorenzi, Thijs van Dalen, Konstantinos Tryfonidis, Martine Piccart, Fátima Cardoso, Emiel J. Rutgers	10
15	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study 2017 ·Breast Cancer Research and Treatment ·Konstantinos Tryfonidis, Sandrine Marréaud, Hussein Khaled, B. De Valk, Jan B. Vermorken, Marzena Wełnicka-Jaśkiewicz, K.C. Aalders, John M.S. Bartlett, Laura Biganzoli, Jan Bogaerts, David Cameron, (unknown)	2
16	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program 2017 ·European Journal of Cancer ·Marijn A. Vermeulen, Leen Slaets, Fátima Cardoso, Sharon H. Giordano, Konstantinos Tryfonidis, P. J. van Diest, (unknown), Carolien P. Schröder, Christi J. van Asperen, Barbro Linderholm, Kim Benstead, Renée Foekens, John W.M. Martens, John M.S. Bartlett, Carolien H. M. van Deurzen	68
17	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives 2017 ·Cancer Treatment Reviews ·K.C. Aalders, Konstantinos Tryfonidis, Elżbieta Senkus, Fátima Cardoso	98
18	Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumor suppressor in breast cancer 2016 ·Annals of Oncology ·Nathan Touati, Konstantinos Tryfonidis, Franco Caramia, Hervé Bonnefoi, David Cameron, Leen Slaets, Belinda S. Parker, Sherene Loi	2
19	Management of locally advanced breast cancer—perspectives and future directions 2015 ·Nature Reviews Clinical Oncology ·Konstantinos Tryfonidis, Elżbieta Senkus, Maria João Cardoso, Fátima Cardoso	116
20	A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13. 2014 ·Journal of Clinical Oncology ·Konstantinos Tryfonidis, Jan Bogaerts, Robert E. Martell, George W. Sledge, Judith Balmañà, M. William Audeh, (unknown), (unknown), Shefali Agarwal, (unknown), Carlo Messina, Leen Slaets, Theodora Goulioti, Andrew Tutt, David Cameron, Nicholas C. Turner	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact